Parkinson's Disease Research & Education Institute

Pimavanserin (Nuplazid™)has been approved by the US Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The drug’s manufacturer, Acadia Pharmaceuticals Inc., announced the approval on April 29. Pimavanserin is the first drug indicated specifically to treat symptoms of psychosis in Parkinson’s.

Better treatment starts with better research. Today, we know that some people with Parkinson’s are able to live well for decades with only minimal impact from their disease. Our research is focused on understanding how these people — and their doctors — are able to achieve these excellent results.  Our goal is to help others apply what we learn to their own unique condition.

 Our mission is to help find the cure for Parkinson's disease and until that goal is achieved, to provide the aid and education needed to combat the detrimental and life-threatening complications of this terrible disease.

mission statement